home

Creating the ideal immunotherapy

Vaxil’s Lead Products and Orphan Drug Status

Vaxil believes its immunotherapy platform allows it to target high profile cancer antigens in a uniquely superior manner, all designed to possess the novel advantages described above. Vaxil’s first test of its VaxHit™ platform is ​its Immucin™; ​lead immunotherapy product.

Vaxil’s development is supported by Six specialized immunology scientists, Four of whom received PhD’s at the Weizmann Institute, Israel’s top scientific university. The Company has developed a robust scientific IP. Research & clinical trial data have been published in high-impact-factor medical journals, all patients treated at top medical centers. VAXIL TRIALS CONDUCTED AT TOP MEDICAL SITES AND RESEARCH PUBLISHED IN THE BEST MEDICAL JOURNALS.


TO DOWNLOAD
TO DOWNLOAD
TO DOWNLOAD
TO DOWNLOAD
TO DOWNLOAD
TO DOWNLOAD logo-inmucin-slider

Vaxil was founded by Weizmann Institute scientists, Israel’s top research university,

in order to provide an altogether novel approach to immunotherapy. Vaxil has diligently advanced its immunotherapy platform and published its research and clinical results in top medical journals.


Learn More


Learn More


Learn More


Learn More

VAXIL’S PRIMARY PLATFORM GENERATES COMPREHENSIVE IDENTIFICATION, ISOLATION & PRODUCTION OF ANTIGEN-SPECIFIC IMMUNOTHERAPIES Vaxil’s VaxHit™ platform technology combines proprietary algorithms which enable in-silico identification of signal peptides domains and their subsequent use as immunotherapeutic products. The VaxHit™ platform is essentially a launchpad for novel and uniquely targeted immunotherapy products. Learn More


Vaxil’s team includes executives and scientists with deep industry experience in Israel, the US, and Canada. Supporting Vaxil’s immunotherapy platform development are six specialized PhD scientists.


Learn More


Learn More


Learn More


Learn More


Learn More


Learn More


Learn More


Category: Cancer-2

Similar articles: